Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
next
study
previous
study
c19early.org COVID-19 treatment researchDanicopanDanicopan (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   All Outcomes       

ACTIV-5 /​ Big Effect Trial (BET-C) for the Treatment of COVID-19

Beigel et al., NCT04988035, ACTIV-5 BET-C, NCT04988035
Apr 2022  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality -43% Improvement Relative Risk Ventilation -17% Recovery -54% Improvement, 2 categories -37% Improvement, 1 category -30% Hospitalization time -19% Danicopan  ACTIV-5 BET-C  LATE TREATMENT  DB RCT Is late treatment with danicopan beneficial for COVID-19? Double-blind RCT 201 patients in the USA Worse recovery with danicopan (p=0.015) c19early.org Beigel et al., NCT04988035, April 2022 Favorsdanicopan Favorscontrol 0 0.5 1 1.5 2+
RCT 201 hospitalized COVID-19 patients showing increased risk with danicopan treatment, with statistical significance for time to sustained recovery.
risk of death, 42.6% higher, RR 1.43, p = 0.34, treatment 19 of 98 (19.4%), control 14 of 103 (13.6%).
risk of mechanical ventilation, 16.8% higher, RR 1.17, p = 0.69, treatment 16 of 91 (17.6%), control 14 of 93 (15.1%), mechanical ventilation or ECMO.
risk of no recovery, 53.8% higher, HR 1.54, p = 0.01, treatment 96, control 99, inverted to make HR<1 favor treatment, Cox proportional hazards.
risk of no improvement, 37.0% higher, HR 1.37, p = 0.06, treatment 96, control 99, inverted to make HR<1 favor treatment, 2 categories, Cox proportional hazards.
risk of no improvement, 29.9% higher, HR 1.30, p = 0.11, treatment 96, control 99, inverted to make HR<1 favor treatment, 1 category, Cox proportional hazards.
hospitalization time, 18.8% higher, relative time 1.19, p = 0.40, treatment median 9.5 IQR 19.0 n=96, control median 8.0 IQR 14.0 n=99.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Beigel et al., 23 Apr 2022, Double Blind Randomized Controlled Trial, placebo-controlled, USA, preprint, 1 author, trial NCT04988035 (history) (ACTIV-5 BET-C). Contact: jbeigel@niaid.nih.gov.
This PaperDanicopanAll
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit